Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $61.00

Posted by Geri Gentry on Nov 12th, 2026

Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price hoisted by Morgan Stanley from $57.00 to $61.00 in a report issued on Monday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Company upped their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Barclays increased their price target on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Thursday, October 15th. Cantor Fitzgerald boosted their price objective on Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Finally, Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average price target of $64.08.

Read Our Latest Analysis on CLDX

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $30.15 on Monday. The firm’s fifty day moving average is $32.41 and its 200-day moving average is $32.74. Celldex Therapeutics has a 52 week low of $22.33 and a 52 week high of $45.14. The firm has a market cap of $2.37 billion, a P/E ratio of -7.01 and a beta of 1.04.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.06. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.72 million. As a group, sell-side analysts anticipate that Celldex Therapeutics will post -4.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Odyssean LLC acquired a new stake in Celldex Therapeutics in the second quarter worth $3,538,000. Quantinno Capital Management LP increased its stake in Celldex Therapeutics by 178.7% in the first quarter. Quantinno Capital Management LP now owns 65,744 shares of the biopharmaceutical company’s stock valued at $2,085,000 after purchasing an additional 42,158 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Celldex Therapeutics in the second quarter valued at $1,259,000. Bank of America Corp DE increased its stake in Celldex Therapeutics by 70.8% in the first quarter. Bank of America Corp DE now owns 708,647 shares of the biopharmaceutical company’s stock valued at $22,478,000 after purchasing an additional 293,759 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Celldex Therapeutics by 11.5% in the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock valued at $355,120,000 after purchasing an additional 983,195 shares in the last quarter.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.